Original Article: Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. #Nephrology #ChronicKidneyDisease #Vasculitis
Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis.
Mentions
Extended reach
Total likes
Video views
Mentions per month
Feb 2020 – Aug 2025Where it's discussed
-
X / Twitter197 posts
-
Facebook12 posts
-
News9 articles
-
Blogs6 articles
-
YouTube3 videos
-
Bluesky1 posts
AI synopsis
What people are saying
Several digital discussions highlight the implications of the PEXIVAS trial, with users noting the lack of benefit from plasma exchange and the advantages of a reduced glucocorticoid regimen. Comments such as 'less is more' and 'a paradigm shift' reflect an optimistic tone towards adopting these findings in clinical practice. The overall positive language and mentions of the study in various contexts contribute to a sentiment of eagerness to integrate these insights into patient care.
Many discussions reflect a general acceptance of the study's findings, particularly regarding glucocorticoid dosing.
There is considerable curiosity and relevance shown, with users expressing strong interest in exploring the implications of the research.
Some participants demonstrate a moderate level of engagement by discussing related studies and sharing insights from the publication, indicating a thoughtful exchange.
A significant number of users perceive the findings as impactful, particularly the potential benefits of the reduced glucocorticoid dosage.
Abstract in brief
- A study was conducted to find safer, more effective treatments for severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis using plasma exchange and different doses of oral glucocorticoids.
- Outcomes showed that plasma exchange did not significantly decrease death or end-stage kidney disease compared to no plasma exchange, while a reduced-dose glucocorticoid regimen was found to be noninferior to the standard dose, with less serious infections.
- The results highlight that although plasma exchange didn't show a major benefit, the reduced-dose glucocorticoid option could be a safer alternative for patients with this condition.
Top posts
Most liked on X and BlueskyOn the basis of the findings of the PEXIVAS trial, the use of plasma exchange does not benefit most patients with ANCA associated Vasculitis (AAV) #Nephpearls
Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis ca. 2020 from @NEJM #Nephpearls #NephJC #VisualAbstract by @NephroGuy
Fussner @LynnFussner et al. DAH in PEXIVAS. DAH more freq younger, PR3+, relapsing, higher disease activity, higher creatinine. DAH more likely to die at 30 days and 1 year than those without DAH @RheumNow #ACR22 Abstr#0526 https://t.co/XGYHvDkVeA https://t.co/IEOcQHEQ3e
Pillar 4 for CKD: Finerenone Or Any MRA? Awaiting @lastwalsh's ACHIEVE study, here comes MAGMA More at HOMe: https://t.co/GmO8RfyKqs https://t.co/s8bAelBksG https://t.co/l2nMWsYDv3
2/ El ensayo PEXIVAS fue un randomizado controlado fase 3 que evaluó la efectividad y seguridad del procedimiento de intercambio de plasma (plasmaferesis) en pacientes con ANCA-vasculitis grave (nefritis o hemorragia pulmonar). No encontraron beneficio. https://t.co/wnSahxo5Jq
All mentions
Mineralocorticoid Antagonists in Advanced Kidney Disease
Explore the evidence behind mineralocorticoid receptor antagonists (MRA) in advanced chronic kidney disease (CKD). Experts discuss trial outcomes, including insights from ALCHEMIST SPIREN and ACHIEVE. Learn from leading…
Best Practices for Glucocorticoid Therapy in Lupus Nephritis
Dr. Ali Duarte Garcia discusses optimal steroid treatment strategies for lupus nephritis patients based on his recent review in Nephrology Dialysis Transplantation. This session covers effective management approaches…
Plasmaférese e Vasculite ANCA
Prof. Walsh (ACHIEVE) @MarkusAtHome https://t.co/3UXXLNgloc Prof. Rossignol (ALCHEMIST) @MarkusAtHome https://t.co/rBqqVkqbp4 @AKronbichler @sara___helena @MarcusSaemann
RT @gunnar_heine: It's again LUPUS @MarkusAtHome Our @NDTsocial Special with @AliDuarteMD Hosts: @AKronbichler @hjanders_hans Prof. Ki…
RT @gunnar_heine: It's again LUPUS @MarkusAtHome Our @NDTsocial Special with @AliDuarteMD Hosts: @AKronbichler @hjanders_hans Prof. Ki…
Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis | New England Journal of Medicine https://t.co/4o8wImGwvn
RT @gunnar_heine: It's again LUPUS @MarkusAtHome Our @NDTsocial Special with @AliDuarteMD Hosts: @AKronbichler @hjanders_hans Prof. Ki…
Optimal Glucocorticoid Therapy in Lupus Nephritis - Dr. Ali Duarte Garcia (Rochester, MN, USA) https://t.co/pyuX83jbdC
Watch now! Optimal Glucocorticoid Therapy in Lupus Nephritis - @AliDuarteMD (Rochester, MN, USA @MayoClinic ) https://t.co/QhaFaczgXY He presents topical ideas on the best use of steroid treatment in patients with systemic lupus erythematosus in nephrology. @NDTsocial
It's again LUPUS @MarkusAtHome Our @NDTsocial Special with @AliDuarteMD Hosts: @AKronbichler @hjanders_hans Prof. Kirsten de Groot https://t.co/HbpFNxlOjL via @YouTube
Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis | New England Journal of Medicine https://t.co/MSyvr5jgUR
4/ AAV leads to pauci-immune necrotizing crescentic glomerulonephritis (NCGN),
Admittedly, it was the third spironolactone failure in a row - after ALCHEMIST and SPIREN. More @ HOMe https://t.co/wQ6SH5zRMa @dguerrot @PStoneOftheYear @lastwalsh @hswapnil @MarcusSaemann @AKronbichler @Tobias_B_Huber @YoungDgk @dgfn_ev @AntMarlies @GlassockJ
@hagilani @lastwalsh Some small & medium-sized RCT specifically in advanced CKD (MIRENDA, DOHAS, ALCHEMIST) + subgroup analysis from landmark studies - in which MRA were at least as protective in CKD G 3 pat as in pat with intact kidney function with regular K checks. More at https://t.co/rqumUyBydG
RT @gunnar_heine: Pillar 4 for CKD: Finerenone Or Any MRA? Awaiting @lastwalsh's ACHIEVE study, here comes MAGMA More at HOMe: https://t.c…
RT @gunnar_heine: Pillar 4 for CKD: Finerenone Or Any MRA? Awaiting @lastwalsh's ACHIEVE study, here comes MAGMA More at HOMe: https://t.c…
RT @gunnar_heine: Pillar 4 for CKD: Finerenone Or Any MRA? Awaiting @lastwalsh's ACHIEVE study, here comes MAGMA More at HOMe: https://t.c…
RT @gunnar_heine: Pillar 4 for CKD: Finerenone Or Any MRA? Awaiting @lastwalsh's ACHIEVE study, here comes MAGMA More at HOMe: https://t.c…
Pillar 4 for CKD: Finerenone Or Any MRA? Awaiting @lastwalsh's ACHIEVE study, here comes MAGMA More at HOMe: https://t.co/GmO8RfyKqs https://t.co/s8bAelBksG https://t.co/l2nMWsYDv3
RT @gunnar_heine: Royal stage of #Touracadémique 2024: Three experts, three trials, five countries
Royal stage of #Touracadémique 2024: Three experts, three trials, five countries
Notre étape reine avec @lastwalsh Patrick Rossigol Dr Line Mortensen @dguerrot @com_SFNDT @dgfn_ev @oegnephro Mineralocorticoid Antagonists in CKD https://t.co/UTsJMJEXrz via @YouTube
RT @JonathanNefro: En VASCULITIS ANCA severa (creat 3.7mg/dL, 27% hemorragia pulmonar) tratar con PLASMAFERESIS tuvo la MISMA frecuencia de…
RT @arvindcanchi: At the GN webinar, @koyaljainMD quotes the @lastwalsh paper in @NEJM https://t.co/4U9ZrmFOP2 showing the drastic reductio…
RT @arvindcanchi: At the GN webinar, @koyaljainMD quotes the @lastwalsh paper in @NEJM https://t.co/4U9ZrmFOP2 showing the drastic reductio…
RT @arvindcanchi: At the GN webinar, @koyaljainMD quotes the @lastwalsh paper in @NEJM https://t.co/4U9ZrmFOP2 showing the drastic reductio…
RT @arvindcanchi: At the GN webinar, @koyaljainMD quotes the @lastwalsh paper in @NEJM https://t.co/4U9ZrmFOP2 showing the drastic reductio…
RT @arvindcanchi: At the GN webinar, @koyaljainMD quotes the @lastwalsh paper in @NEJM https://t.co/4U9ZrmFOP2 showing the drastic reductio…
At the GN webinar, @koyaljainMD quotes the @lastwalsh paper in @NEJM https://t.co/4U9ZrmFOP2 showing the drastic reduction in steroid dose (halving the dose at wk 2) in the group on reduced dose steroid in the Pexivas trial. We need to embrace such infection reducing strategies https://t.co/hYPwyk8HWt
RT @DrAbdulAzizQaz1: @IhabFathiSulima latest treatment for ANCA vasculitis. A rapidly reducing glucocorticoid regimen is now preferred—the…
@IhabFathiSulima latest treatment for ANCA vasculitis. A rapidly reducing glucocorticoid regimen is now preferred—the Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis (PEXIVAS) Trial schedule—which reduces risk of serious infection without loss of efficacy.
@NEJM https://t.co/vT7bxfRwZP
RT @GKA_CME: Plasma exchange and #glucocoricoids have shown remarkable results in combatting #AVV. To explore more key findings on ANCA-ass…
Plasma exchange and #glucocoricoids have shown remarkable results in combatting #AVV. To explore more key findings on ANCA-associated vasculitis, click here: https://t.co/NJM6dtoykP #Kidney #MedTwitter
RT @edgarvlermamd: On the basis of the findings of the PEXIVAS trial, the use of plasma exchange does not benefit most patients with ANCA a…
RT @edgarvlermamd: On the basis of the findings of the PEXIVAS trial, the use of plasma exchange does not benefit most patients with ANCA a…
RT @edgarvlermamd: On the basis of the findings of the PEXIVAS trial, the use of plasma exchange does not benefit most patients with ANCA a…
RT @edgarvlermamd: On the basis of the findings of the PEXIVAS trial, the use of plasma exchange does not benefit most patients with ANCA a…
RT @edgarvlermamd: On the basis of the findings of the PEXIVAS trial, the use of plasma exchange does not benefit most patients with ANCA a…
RT @edgarvlermamd: On the basis of the findings of the PEXIVAS trial, the use of plasma exchange does not benefit most patients with ANCA a…
RT @edgarvlermamd: On the basis of the findings of the PEXIVAS trial, the use of plasma exchange does not benefit most patients with ANCA a…
RT @edgarvlermamd: On the basis of the findings of the PEXIVAS trial, the use of plasma exchange does not benefit most patients with ANCA a…
RT @edgarvlermamd: On the basis of the findings of the PEXIVAS trial, the use of plasma exchange does not benefit most patients with ANCA a…
RT @edgarvlermamd: On the basis of the findings of the PEXIVAS trial, the use of plasma exchange does not benefit most patients with ANCA a…
RT @edgarvlermamd: On the basis of the findings of the PEXIVAS trial, the use of plasma exchange does not benefit most patients with ANCA a…
RT @edgarvlermamd: On the basis of the findings of the PEXIVAS trial, the use of plasma exchange does not benefit most patients with ANCA a…
On the basis of the findings of the PEXIVAS trial, the use of plasma exchange does not benefit most patients with ANCA associated Vasculitis (AAV) #Nephpearls
PEXIVAS (2020) @NEJM Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis 寛解導入 PE & PSL taper ①PEの有無でESKD or 死亡率に有意差なし ② GC減量群でESKD or 死亡率は非劣性 https://t.co/C41BeRy0uS
@tomayates @sanjaybhagani @OutbreakJake Evidence seems to now be showing that “less is more” though however. The PEXIVAS trial in ANCA vasculitis showed lower steroid dose non interior to standard dose steroid and growing data to support lower dosing of IV methylpred in rheum conditions - https://t.co/XmYzvy9SOm
RT @RichardPAConway: Fussner @LynnFussner et al. DAH in PEXIVAS. DAH more freq younger, PR3+, relapsing, higher disease activity, higher cr…
RT @RichardPAConway: Fussner @LynnFussner et al. DAH in PEXIVAS. DAH more freq younger, PR3+, relapsing, higher disease activity, higher cr…
RT @RichardPAConway: Fussner @LynnFussner et al. DAH in PEXIVAS. DAH more freq younger, PR3+, relapsing, higher disease activity, higher cr…
RT @RichardPAConway: Fussner @LynnFussner et al. DAH in PEXIVAS. DAH more freq younger, PR3+, relapsing, higher disease activity, higher cr…
RT @RichardPAConway: Fussner @LynnFussner et al. DAH in PEXIVAS. DAH more freq younger, PR3+, relapsing, higher disease activity, higher cr…
RT @RichardPAConway: Fussner @LynnFussner et al. DAH in PEXIVAS. DAH more freq younger, PR3+, relapsing, higher disease activity, higher cr…
RT @RichardPAConway: Fussner @LynnFussner et al. DAH in PEXIVAS. DAH more freq younger, PR3+, relapsing, higher disease activity, higher cr…
RT @RichardPAConway: Fussner @LynnFussner et al. DAH in PEXIVAS. DAH more freq younger, PR3+, relapsing, higher disease activity, higher cr…
RT @RichardPAConway: Fussner @LynnFussner et al. DAH in PEXIVAS. DAH more freq younger, PR3+, relapsing, higher disease activity, higher cr…
RT @RichardPAConway: Fussner @LynnFussner et al. DAH in PEXIVAS. DAH more freq younger, PR3+, relapsing, higher disease activity, higher cr…
Fussner @LynnFussner et al. DAH in PEXIVAS. DAH more freq younger, PR3+, relapsing, higher disease activity, higher creatinine. DAH more likely to die at 30 days and 1 year than those without DAH @RheumNow #ACR22 Abstr#0526 https://t.co/XGYHvDkVeA https://t.co/IEOcQHEQ3e
To PEX or no to PEX? PLEXIVAS study published on NEJM february 13 , 2020 Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis (https://t.co/HOBthOmHlH) #rheumatology #RheumTwitter #MedTwitter #MedEd #RheumEdu 1/14
RT @MonicaVivek: 15/ PLEX
15/ PLEX
Learning point #3: A study published in NEJM (2020) showed that tx with PLEX, in addition to glucocorticoids, did not reduce the incidence of death or ESRD in pts with severe ANCA-associated vasculitis as compared to glucocorticoids alone. https://t.co/9h2XOopFOb
PEXIVAS Trial, nos muestra cómo no existe diferencia entre esquema reducido de esteroide vs esquema convencional. Sin duda una excelente opción para pacientes con requerimiento de dicho medicamento en otras patologías. https://t.co/uSqeN2M52Y https://t.co/eaNcMJjKCU
RT @HotKidneyAction: First Contender - @RealDr_Pepper runs through OG Pexivas https://t.co/kahnbEkCfk and 2022 meta-analysis https://t.co/…
First Contender - @RealDr_Pepper runs through OG Pexivas https://t.co/kahnbEkCfk and 2022 meta-analysis https://t.co/k4Hcvcy1w0 #UKKW2022
RT @ERAkidney: What about glucocorticoids in an elderly population? More serious infections in high dose GC group but no differences in re…
What about glucocorticoids in an elderly population? More serious infections in high dose GC group but no differences in relapse. https://t.co/b21R75MMDm Similar results in PEXIVAS. https://t.co/Mqf91YfVTu #ERA22 #GLOMera22 https://t.co/KlCAzvITIS
RT @edgarvlermamd: PEXIVAS: In severe ANCA vasculitis, PLEX did not reduce the incidence of death/ ESKD
RT @edgarvlermamd: Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis ca. 2020 from @NEJM #Nephpearls #NephJC #Visua…
RT @edgarvlermamd: Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis ca. 2020 from @NEJM #Nephpearls #NephJC #Visua…
RT @edgarvlermamd: Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis ca. 2020 from @NEJM #Nephpearls #NephJC #Visua…
RT @edgarvlermamd: Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis ca. 2020 from @NEJM #Nephpearls #NephJC #Visua…
RT @edgarvlermamd: Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis ca. 2020 from @NEJM #Nephpearls #NephJC #Visua…
RT @edgarvlermamd: Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis ca. 2020 from @NEJM #Nephpearls #NephJC #Visua…
RT @edgarvlermamd: Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis ca. 2020 from @NEJM #Nephpearls #NephJC #Visua…
RT @edgarvlermamd: Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis ca. 2020 from @NEJM #Nephpearls #NephJC #Visua…
RT @edgarvlermamd: Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis ca. 2020 from @NEJM #Nephpearls #NephJC #Visua…
RT @edgarvlermamd: Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis ca. 2020 from @NEJM #Nephpearls #NephJC #Visua…
RT @edgarvlermamd: Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis ca. 2020 from @NEJM #Nephpearls #NephJC #Visua…
RT @edgarvlermamd: Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis ca. 2020 from @NEJM #Nephpearls #NephJC #Visua…
RT @edgarvlermamd: Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis ca. 2020 from @NEJM #Nephpearls #NephJC #Visua…
Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis ca. 2020 from @NEJM #Nephpearls #NephJC #VisualAbstract by @NephroGuy
Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis ca. 2020 from @NEJM #Nephpearls #NephJC #VisualAbstract by @NephroGuy
‼️RHEUMA JOURNAL CLUB‼️ Plasmaferesi e glucocorticoidi nelle vasculiti ANCA-associate https://t.co/pS5OaUCwPr via @CReI
The primary outcome occurred in 100 patients (28.4%) in the PLEX group and in 109 patients (31.0%) in the control group (HR 0.86, 95% CI 0.65 to 1.13, P=0.27). #DiseaseWeek /10 https://t.co/joe8917E6V https://t.co/cvqh5peE5q
The primary outcome occurred in 92 patients (27.9%) in the reduced-steroid group and in 83 of 325 (25.5%) in the standard-dose group. #DiseaseWeek /6 https://t.co/joe8917E6V https://t.co/DmxumgvIX4
In 2020, we saw the publication of the PEXIVAS trial which showed that a regimen with less steroids was non-inferior to a standard-dose regimen in relation to death and ESKD. #DiseaseWeek /5 https://t.co/joe8917E6V
2/ El ensayo PEXIVAS fue un randomizado controlado fase 3 que evaluó la efectividad y seguridad del procedimiento de intercambio de plasma (plasmaferesis) en pacientes con ANCA-vasculitis grave (nefritis o hemorragia pulmonar). No encontraron beneficio. https://t.co/wnSahxo5Jq
Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis | NEJM https://t.co/kJiWFV6rJl
RT @NephJC: T9c: PLEX is given if AAV overlaps with anti-GBM antibody GN. KDIGO suggests PLEX not be used routinely in AAV. Do you give PLE…
RT @NephJC: T9c: PLEX is given if AAV overlaps with anti-GBM antibody GN. KDIGO suggests PLEX not be used routinely in AAV. Do you give PLE…
T9c: PLEX is given if AAV overlaps with anti-GBM antibody GN. KDIGO suggests PLEX not be used routinely in AAV. Do you give PLEX routinely in AAV? #NephJC PEXIVAS trial https://t.co/ZSnX1P2A9v
@RahulArgula @nickmmark @OnePagerICU @CPSolvers @AnnKumfer @k_vaishnani @DxRxEdu @rabihmgeha @ShreyaTrivediMD @RahulArgula Also great Q on PLEX: in ANCA-associated vasculitis, plasma exchange is controversial but still used in anti-GBM cases. The PEXIVAS trial found use of plasma exchange did not reduce the incidence of death or ESKD, can read more here⬇️ https://t.co/YOTv5kbAu1
RT @ERheumat: #PEXIVAS #Avocapan #vasculitis @NEJM @JWatch #RheumTwitter #rheumatology #ANCA #nephjc #Nephpearls #MedTwitter #autoimmunedis…
RT @ERheumat: #PEXIVAS #Avocapan #vasculitis @NEJM @JWatch #RheumTwitter #rheumatology #ANCA #nephjc #Nephpearls #MedTwitter #autoimmunedis…
RT @ERheumat: #PEXIVAS #Avocapan #vasculitis @NEJM @JWatch #RheumTwitter #rheumatology #ANCA #nephjc #Nephpearls #MedTwitter #autoimmunedis…
RT @ERheumat: #PEXIVAS #Avocapan #vasculitis @NEJM @JWatch #RheumTwitter #rheumatology #ANCA #nephjc #Nephpearls #MedTwitter #autoimmunedis…
RT @ERheumat: #PEXIVAS #Avocapan #vasculitis @NEJM @JWatch #RheumTwitter #rheumatology #ANCA #nephjc #Nephpearls #MedTwitter #autoimmunedis…
RT @ERheumat: #PEXIVAS #Avocapan #vasculitis @NEJM @JWatch #RheumTwitter #rheumatology #ANCA #nephjc #Nephpearls #MedTwitter #autoimmunedis…
RT @ERheumat: #PEXIVAS #Avocapan #vasculitis @NEJM @JWatch #RheumTwitter #rheumatology #ANCA #nephjc #Nephpearls #MedTwitter #autoimmunedis…
RT @ERheumat: #PEXIVAS #Avocapan #vasculitis @NEJM @JWatch #RheumTwitter #rheumatology #ANCA #nephjc #Nephpearls #MedTwitter #autoimmunedis…
#PEXIVAS #Avocapan #vasculitis @NEJM @JWatch #RheumTwitter #rheumatology #ANCA #nephjc #Nephpearls #MedTwitter #autoimmunedisease #meded #visualabstracts #pulmonarycapillaritis Full article: https://t.co/VBmZHGKSnc https://t.co/khQCubsbWt
PEXIVAS。severe ANCA関連血管炎に血漿交換無効というのが衝撃的でしたが、ステロイド高速減量の非劣勢という結果は、今後どのように影響してくるのでしょうか。ステロイドパルス後、体重50kg未満ならPSL50mgで開始、翌週には25mgに減量というのは凄いスピード感です。 https://t.co/Jqj5pdUwIA
RT @slrchiefs: Rheumatology day! As part of one of the activities of our AHD we had a EBM session where we discussed about “Plasma Exchange…
Rheumatology day! As part of one of the activities of our AHD we had a EBM session where we discussed about “Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis” published in NEJM, February 2020. @gosorio @ANABELENAREVAL2 @annatav https://t.co/wwlLuQIeYV
RT @bella_mehta: #ACR20 year in review by @JYazdanyMD latest data PEXIVAS and SEMIRA trials on corticosteroids - would you change your clin…
Dr. Yazdany reviewed 2 Penn-run studies in her “Year in Review: Clinical Science” session at #ACR20! Check them out: PEXIVAS https://t.co/ECOeWznwYX Risk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty https://t.co/gDyv5Ame4h
#ACR20 year in review by @JYazdanyMD latest data PEXIVAS and SEMIRA trials on corticosteroids - would you change your clinical practice to minimize even low dose Corticosteroids in RA and Vasculitis? @RheumNow https://t.co/l7PTyANpjq https://t.co/MRGbsjaGae
@JYazdanyMD ⭐Steroid studies PEXIVAS RCT: plasma exchange in severe AAV after RTX or CYC induction https://t.co/dSPuksLOxx A 2x2 factorial design: also assessed standard GC vs low GC regimen #ACR20 #ACRambassador
RT @edgarvlermamd: PEXIVAS: In severe ANCA vasculitis, plasma exchange did not reduce the incidence of death/ ESKD
RT @EDL1976: En pacientes con vasculitis grave asociada a ANCA's, la plasmaféresis no confirió una disminución en la mortalidad y en la inc…
RT @edgarvlermamd: PEXIVAS: In severe ANCA vasculitis, PLEX did not reduce the incidence of death/ ESKD
RT @edgarvlermamd: PEXIVAS: In severe ANCA vasculitis, PLEX did not reduce the incidence of death/ ESKD
RT @edgarvlermamd: PEXIVAS: In severe ANCA vasculitis, PLEX did not reduce the incidence of death/ ESKD
RT @edgarvlermamd: PEXIVAS: In severe ANCA vasculitis, PLEX did not reduce the incidence of death/ ESKD
PLEX or no PLEX? Question answered by PEXIVAS trial. No PLEX performed. https://t.co/SSizfFDK59 https://t.co/QhLU7fu6mZ
RT @edgarvlermamd: PEXIVAS: In severe ANCA vasculitis, plasma exchange did not reduce the incidence of death/ ESKD
RT @EUVAS19:
RT @Artritis_Celso: PEXIVAS Trial. NEJM No hubo diferencias sigificativas para muertes y/o enfermedad renal terminal en pacts con Vasculit…
RT @Artritis_Celso: PEXIVAS Trial. NEJM No hubo diferencias sigificativas para muertes y/o enfermedad renal terminal en pacts con Vasculit…
RT @Artritis_Celso: PEXIVAS Trial. NEJM No hubo diferencias sigificativas para muertes y/o enfermedad renal terminal en pacts con Vasculit…
PEXIVAS Trial. NEJM No hubo diferencias sigificativas para muertes y/o enfermedad renal terminal en pacts con Vasculitis ANCA , q recibieron plasmaféresis vs. sin plasmaféresis. Tampoco No inferioridad , con dosis bajas d esteroides vs. dosis standar. https://t.co/Q2TDJxgj2Y
Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis https://t.co/3PQqKfBKQ2 #ubc #nephrology
RT @AnnKumfer: 4/Some articles: plasma exchange in ANCA https://t.co/4pCBTyrzET Rituximab vs cyclophosphamide https://t.co/Fd59yS6BwC ht…
4/Some articles: plasma exchange in ANCA https://t.co/4pCBTyrzET Rituximab vs cyclophosphamide https://t.co/Fd59yS6BwC https://t.co/XVxpmsi2gk
Plasma exchange & glucocorticoids do not impact long-term survival in ANCA-associated #vasculitis, according to a study w/Peter A. Merkel @PennMedicine, PI of #RDCRN's Vasculitis Clinical Research Consortium. Press release: https://t.co/8SMGg9sf3D Study: https://t.co/RTLL7ATSxY https://t.co/jpyh1YAwL7
https://t.co/oqs9rPfCgO
RT @Antonio28774221: https://t.co/C7D13C4e9d
RT @Antonio28774221: https://t.co/C7D13C4e9d
RT @Antonio28774221: https://t.co/C7D13C4e9d
RT @Antonio28774221: https://t.co/C7D13C4e9d
https://t.co/C7D13C4e9d https://t.co/Yvetseg504
重症ANCA関連血管炎での血漿交換と #ステロイド 減量レジメンを検証した2×2要因RCT。PSLの標準治療群が意外と多い印象。CYCLOPSのスケジュールとそんなに変わっていないかな。 #AAV Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis | NEJM https://t.co/3xkH4Q6BjZ https://t.co/1XsiAwdr50
Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis [...] Patients were randomly assigned to undergo plasma exchange (seven plasma exchanges within 14 days after randomization) or no plasma exchange (control group). [...] https://t.co/BKhs9GHpoA https://t.co/NnKLfwjKSX
@r_aravinth_ https://t.co/jTdzwz4AFy
Tem conteúdo novo no Blog da SBN do Dr. Rui Toledo Barros, acesse: https://t.co/3kK2dGZf6u #SBN #BlogCientífico #Nefrologia https://t.co/SO9VpHIDSq
RT @FarmaCHUS:
RT @ChrisTormey3: With PEXIVAS trial now published (https://t.co/bLP3Ub5NkQ), I am wondering how my colleagues in transfusion medicine and…
RT @FarmaCHUS:
RT @EDL1976: En pacientes con vasculitis grave asociada a ANCA's, la plasmaféresis no confirió una disminución en la mortalidad y en la inc…
En pacientes con vasculitis grave asociada a ANCA's, la plasmaféresis no confirió una disminución en la mortalidad y en la incidencia de ERCT. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis | NEJM https://t.co/eUJSOUqcEc
RT @RostronTony: Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis | NEJM https://t.co/UPL0TU9J9H
RT @andykimpharmd: The trend for "less steroids is just as good," continues! #PharmICU
The trend for "less steroids is just as good," continues! #PharmICU
RT @ukivas: Excellent visual abstract to summarise an important paper published in the Feb edition of NEJM 'Plasma Exchange and Glucocort…
RT @Renalpathsoc: Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis | NEJM https://t.co/si3He2NJz7
RT @ukivas: Excellent visual abstract to summarise an important paper published in the Feb edition of NEJM 'Plasma Exchange and Glucocort…
RT @ukivas: Excellent visual abstract to summarise an important paper published in the Feb edition of NEJM 'Plasma Exchange and Glucocort…
RT @ukivas: Excellent visual abstract to summarise an important paper published in the Feb edition of NEJM 'Plasma Exchange and Glucocort…
Excellent visual abstract to summarise an important paper published in the Feb edition of NEJM 'Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis' https://t.co/TeCVwcyIVR https://t.co/G0SJcZu8Wc
Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis | NEJM https://t.co/si3He2NJz7
#NIAMSResearch @PennMedicine: “Plasma Exchange and Glucocorticoids in Severe ANCA-Associated #Vasculitis” https://t.co/dlS39MKFEp. Abstract only. Full access requires subscription or payment. @nejm. Additional funding: @fda
Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. N Engl J Med #cancer #epidemiology https://t.co/GivuaHAR4A
RT @NephJC: T-1 hour to #NephJC chat tonight at 9 pm. We will be discussing the use of plasma exchange and glucocorticoids in severe ANCA a…
T-1 hour to #NephJC chat tonight at 9 pm. We will be discussing the use of plasma exchange and glucocorticoids in severe ANCA associated vasculitis. Come join us!
RT @NephJC: T-1 hour to #NephJC chat tonight at 9 pm Indian Standard Time. We will be discussing the use of plasma exchange and glucocortic…
RT @NephJC: T-1 hour to #NephJC chat tonight at 9 pm Indian Standard Time. We will be discussing the use of plasma exchange and glucocortic…
T-1 hour to #NephJC chat tonight at 9 pm Indian Standard Time. We will be discussing the use of plasma exchange and glucocorticoids in severe ANCA associated vasculitis. Come join us! Link to @NEJM journal article - https://t.co/iUSDyicZPt #NephJC
RT @fadelrowaie: #فضفضة_طبيب Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis https://t.co/KY5113FkPZ
Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis | NEJM https://t.co/dTyHM1dt9r
RT @NEJM: Original Article: Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. #Nephrology #ChronicKidneyDisease #Va…
RT @NEJM: Original Article: Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. #Nephrology #ChronicKidneyDisease #Va…
RT @NEJM: Original Article: Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. #Nephrology #ChronicKidneyDisease #Va…
RT @NEJM: Original Article: Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. #Nephrology #ChronicKidneyDisease #Va…
RT @NEJM: Original Article: Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. #Nephrology #ChronicKidneyDisease #Va…
RT @NEJM: Original Article: Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. #Nephrology #ChronicKidneyDisease #Va…
Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis | NEJM https://t.co/CWbsLlKdys
RT @NEJM: Original Article: Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. #Nephrology #ChronicKidneyDisease #Va…
RT @NEJM: Original Article: Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. #Nephrology #ChronicKidneyDisease #Va…
RT @NEJM: Original Article: Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. #Nephrology #ChronicKidneyDisease #Va…
RT @NEJM: Original Article: Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. #Nephrology #ChronicKidneyDisease #Va…
RT @NEJM: Original Article: Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. #Nephrology #ChronicKidneyDisease #Va…
RT @NEJM: Original Article: Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. #Nephrology #ChronicKidneyDisease #Va…
RT @NEJM: Original Article: Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. #Nephrology #ChronicKidneyDisease #Va…
RT @NEJM: Original Article: Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. #Nephrology #ChronicKidneyDisease #Va…
RT @NEJM: Original Article: Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. #Nephrology #ChronicKidneyDisease #Va…
Original Article: Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. #Nephrology #ChronicKidneyDisease #Vasculitis
How will this affect your practice? #vasculitis #plasmaexchange #PLEX #ANCA Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis | NEJM https://t.co/L3rmZZBIZP
RT @LuisAlvarezRa: Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis | NEJM https://t.co/Pg1xYvoj9f
Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis | NEJM https://t.co/E59DPFA2AJ
Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis | NEJM https://t.co/ZsDrDrZNel
RT @LuisAlvarezRa: Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis | NEJM https://t.co/Pg1xYvoj9f
RT @RostronTony: Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis | NEJM https://t.co/UPL0TU9J9H
Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis | NEJM https://t.co/Pg1xYvoj9f
Trend up+4: *Walsh M* et al (N Engl J Med) __Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis__ https://t.co/oPyA4qxRHl
Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis | NEJM https://t.co/UPL0TU9J9H
Wie therapiert man eine pANCA Vaskulitis bzw. was ist nutzlos? Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis https://t.co/0xabxAgsCe https://t.co/DSvecCGGfN
Trend new: *Walsh M* et al (N Engl J Med) __Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis__ https://t.co/oPyA4qxRHl
Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis https://t.co/RqxwtgceVT
RT @vasculitides: Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. - PubMed - NCBI https://t.co/ZBJcDFuXx8
RT @vasculitides: Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. - PubMed - NCBI https://t.co/ZBJcDFuXx8
RT @vasculitides: Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. - PubMed - NCBI https://t.co/ZBJcDFuXx8
RT @fadelrowaie: #فضفضة_طبيب Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis https://t.co/KY5113FkPZ
Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. - PubMed - NCBI https://t.co/ZBJcDFuXx8
RT @Reuma_Online_: Por fin en @NEJM. Dará mucho de que hablar. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis…
Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis | NEJM https://t.co/NBAFSW2z4U
Published #pexivas https://www.nejm.org/doi/full/10.1056/NEJMoa1803537